Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study

In vitro data suggest the monoclonal antibody sotrovimab may have lost inhibitory capability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. We aimed to provide real-life data on clinical outcomes in hospitalized patients. We retrospectively analyzed patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Marcel S., Brehm, Thomas Theo, Fischer, Marlene, Heyer, Andreas, Wichmann, Dominic, Jordan, Sabine, Nörz, Dominik, Lütgehetmann, Marc, Addo, Marylyn M., Lohse, Ansgar W., Schmiedel, Stefan, Kluge, Stefan, Schulze zur Wiesch, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927465/
https://www.ncbi.nlm.nih.gov/pubmed/36475890
http://dx.doi.org/10.1128/spectrum.04103-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927465/
https://www.ncbi.nlm.nih.gov/pubmed/36475890
http://dx.doi.org/10.1128/spectrum.04103-22

Ejemplares similares